Cargando…
Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products()
Several companies were authorized to treat COVID-19 patients with monoclonal antibodies within 1–2 years of the start of the pandemic. These products were discovered, developed, manufactured, clinically tested, and approved under emergency-use authorization at unprecedented speed. Pandemic urgency l...
Autores principales: | Kelley, Brian, De Moor, Pam, Douglas, Kristen, Renshaw, Todd, Traviglia, Stacey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436891/ https://www.ncbi.nlm.nih.gov/pubmed/36179406 http://dx.doi.org/10.1016/j.copbio.2022.102798 |
Ejemplares similares
-
Development and validation of a platform reduced intact mass method for process monitoring of monoclonal antibody glycosylation during routine manufacturing
por: Schilling, Michael, et al.
Publicado: (2020) -
Developing therapeutic monoclonal antibodies at pandemic pace
por: Kelley, Brian
Publicado: (2020) -
Monoclonal antibodies as anti-infective products: a promising future?
por: Pelfrene, E., et al.
Publicado: (2019) -
Future of Monoclonal Antibody Therapy in Parkinson’s Disease
por: Kharel, Sanjeev, et al.
Publicado: (2022) -
Long COVID Syndrome: Lesson Learned and Future Implications
por: Mazzaglia, Giampiero
Publicado: (2023)